As part of a planned expansion of their Bulk Active Pharmaceutical Ingredients (API) capacity, Macfarlan Smith Ltd commissioned Austin to design and construct a new production facility on their manufacturing site in Edinburgh, Scotland.

The building occupies a total area of 1,000m² on four floors and produces a multiple range of primary pharmaceutical products.

The process equipment includes five 2.5m³ reactors, each controlled by a dedicated single fluid heat/cool package. Finished product is dried and packaged using pressure filter drier technology in a controlled environment.

The new plant is designed and constructed to meet cGMP requirements and is fully validated.

In addition, the plant has been designed to comply with the requirements of the relevant authorities in respect of the control of emission into the atmosphere and drainage system.